Poststroke Depression in Hemorrhagic Stroke
Status and phase
Conditions
Treatments
Details and patient eligibility
About
A double-blinded placebo-controlled randomized trial to evaluate the effect of preventative treatment of depression in survivors of aneurysmal subarachnoid hemorrhage (aSAH), a type of stroke.
Full description
Patients who suffered aneurysmal subarachnoid hemorrhage will be randomly assigned either an oral antidepressant or placebo and evaluated for the preventative treatment of depression and health-related quality-of-life.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients 18-85 years of age aged 18 years and older will be included.
Patients admitted for subarachnoid hemorrhage from a ruptured cerebral aneurysm will be included.
Only patients who provide informed consent will be included.
Exclusion criteria
Non-English speaking patients will be excluded.
Patients currently receiving therapy for depression or related mental health diagnoses before admission will be excluded.
Patients with medical contraindications to fluoxetine therapy will be excluded.
Pregnant patients or patients considering pregnancy during the trial period at the time of consent will be excluded.
Patients with active psychosis will be excluded.
Patients who are incarcerated or in police custody will be excluded.
Patients with a comorbidity or cognitive impairment (as determined by a recruiter-administered Montreal Cognitive Assessment; Patients scoring >26 are considered of appropriate cognitive function for consent) that precludes informed consent and participation in the research interviews will be excluded.
Trial design
Primary purpose
Allocation
Interventional model
Masking
8 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Central trial contact
Do Lim
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal